Adebrelimab
GLUT3
Fudan UniversityPhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 89/ 100
Competitive context
5 Active assets in the GLUT3 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Eloxatin Fudan University | Phase 3 | B |
FLUOROURACILUM Fudan University | Phase 3 | B |
Carboplatin Fudan University | Phase 3 | B |
ETOPOSIDE Fudan University | Phase 3 | B |
Calcium folinate pentahydrate Fudan University | Phase 3 | B |
Same molecule, other indications
Adebrelimab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →